Description

Product Description

Recombinant Human G-CSF Injection is a purified protein expressed in mammalian or bacterial expression systems and formulated for laboratory and preclinical research. As a key hematopoietic growth factor, G-CSF regulates the production, differentiation, and functional activation of neutrophils, the primary effector cells of innate immunity.

This injection is commonly used in in vitro cell culture systems, ex vivo differentiation studies, and animal models of neutropenia, bone marrow suppression, or immune deficiency. By providing a consistent recombinant source, researchers can investigate the molecular mechanisms of granulopoiesis, receptor signaling, and downstream effector functions under controlled experimental conditions.

G-CSF binds to the specific G-CSF receptor (G-CSFR) expressed on hematopoietic progenitor cells, activating intracellular JAK/STAT, PI3K/AKT, and MAPK signaling pathways. These cascades regulate gene transcription, cell survival, proliferation, and differentiation. Preclinical studies utilizing G-CSF injection have demonstrated enhanced neutrophil recovery following chemotherapy or irradiation, as well as accelerated hematopoietic reconstitution in stem cell transplantation models.

Recombinant Human G-CSF Injection is formulated under aseptic conditions and provided as a lyophilized powder or ready-to-use solution, ensuring stability and reproducibility for experimental protocols. Researchers may employ it in combination with other growth factors, cytokines, or chemotherapeutic agents to explore synergistic or modulatory effects on hematopoietic and immune cells.

Product Specifications

Mechanism of Action

Recombinant Human G-CSF Injection functions as a hematopoietic growth factor, specifically promoting the proliferation, differentiation, and functional activation of neutrophil precursors. Its mechanism of action is multifaceted, involving receptor-mediated signaling and transcriptional regulation.

1. Receptor Binding and Signal Activation

G-CSF binds to the G-CSF receptor (G-CSFR) on hematopoietic stem and progenitor cells. Ligand binding induces receptor dimerization and conformational changes that activate intracellular signaling cascades including:

• JAK/STAT pathway: Promotes transcription of genes regulating proliferation and survival.

• PI3K/AKT pathway: Enhances anti-apoptotic signals and metabolic activity.

• MAPK pathway: Facilitates cell cycle progression and differentiation.

These pathways collectively stimulate granulopoiesis and support the maturation of neutrophilic lineage cells.

2. Neutrophil Proliferation and Differentiation

Upon G-CSFR activation, committed myeloid progenitor cells differentiate into mature neutrophils. This results in an increase in circulating neutrophils and functional granulocyte activity in experimental models.

3. Modulation of Immune Function

G-CSF not only drives neutrophil production but also modulates immune responses by enhancing phagocytic activity, reactive oxygen species generation, and cytokine production. These effects are leveraged in laboratory studies of innate immunity, infection models, and inflammatory regulation.

4. Hematopoietic Recovery in Preclinical Models

G-CSF is widely used to accelerate bone marrow recovery after chemotherapy, irradiation, or myelosuppressive treatments in animal studies. It stimulates progenitor expansion, reduces neutropenic periods, and improves experimental survival outcomes.

5. Synergistic and Experimental Applications

In laboratory research, G-CSF is frequently combined with other growth factors such as GM-CSF, SCF, or EPO to study cooperative hematopoietic effects, stem cell mobilization, and lineage-specific differentiation in vitro and in vivo.

Side Effects

Recombinant Human G-CSF Injection is intended strictly for laboratory and preclinical research. Considerations include:

• Potential overstimulation of neutrophil proliferation in animal models if doses exceed experimental requirements;

• Risk of hematopoietic imbalance or off-target lineage effects;

• Protein aggregation or instability if stored improperly;

• Necessity for sterile handling and precise dosing.

These injections are not intended for human use and should be handled according to institutional biosafety guidelines.

Keywords

Recombinant Human G-CSF Injection, Filgrastim, rHuG-CSF, neutrophil differentiation, hematopoietic growth factor, preclinical immunology research, bone marrow recovery, cytokine research, high-purity recombinant protein

Shipping Guarantee

All Recombinant Human G-CSF shipments are handled using validated cold-chain logistics to preserve protein bioactivity. Each package is sealed in moisture-proof containers with secondary protective wrapping. Products are shipped via express international couriers with full tracking and insurance coverage.

Trade Assurance

We Recombinant Human G-CSF ensure product authenticity, verified ≥99% purity, and compliance with analytical standards (SDS-PAGE, HPLC). Each batch is supplied with a Certificate of Analysis (CoA). Our trade assurance policy guarantees replacement or refund for any deviation from listed specifications.

Payment Support

We Recombinant Human G-CSF provide flexible and secure global payment options to support international research transactions. Accepted payment methods include PayPal, major credit cards (Visa, MasterCard, American Express), telegraphic transfer (T/T), and cryptocurrencies (USDT, Bitcoin, Ethereum). All transactions are protected by industry-standard encryption and verified payment gateways to ensure confidentiality and fund security.

Disclaimer

All Recombinant Human G-CSF products listed are intended for laboratory and preclinical research use only and not for human or veterinary use. They are not drugs, medical devices, or diagnostics and should not be administered to humans or animals. Researchers must handle all materials in accordance with institutional biosafety and chemical safety guidelines. The information provided is for scientific reference only and does not imply therapeutic efficacy, safety, or regulatory approval.